The popularity of Viagra initially drove a period of growth for pharma, however recent changes present a murky outlook for shareholders. Lower-cost versions are reducing earnings, and persistent patent challenges add https://flynnuvma617493.suomiblog.com/the-blue-pill-and-big-pharma-a-volatile-bet-57006776